DaVita Inc. (NYSE:DVA) Given Average Rating of “Hold” by Analysts

Shares of DaVita Inc. (NYSE:DVA) have been given a consensus recommendation of “Hold” by the eight brokerages that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $221.75.

Several equities analysts have recently issued reports on the company. Zacks Research cut DaVita from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Raymond James Financial set a $220.00 target price on DaVita in a report on Friday, August 7th. UBS Group lifted their price target on DaVita from $235.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, July 10th. Barclays upped their price objective on DaVita from $218.00 to $224.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 5th. Finally, Weiss Ratings raised shares of DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 5th.

DaVita Price Performance

DVA traded up $0.56 on Monday, reaching $174.38. 75,239 shares of the stock were exchanged, compared to its average volume of 944,961. The company’s 50-day moving average price is $214.96 and its 200 day moving average price is $182.03. DaVita has a fifty-two week low of $101.00 and a fifty-two week high of $247.49. The firm has a market capitalization of $11.13 billion, a PE ratio of 14.27, a PEG ratio of 0.58 and a beta of 0.88.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.88 by $0.14. The firm had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.50 billion. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period last year, the business posted $2.95 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, equities analysts forecast that DaVita will post 14.57 earnings per share for the current fiscal year.

Insider Transactions at DaVita

In related news, insider Kathleen Alyce Waters sold 15,405 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the sale, the insider owned 109,194 shares in the company, valued at approximately $22,756,029.60. This trade represents a 12.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.90% of the company’s stock.

Institutional Investors Weigh In On DaVita

Several hedge funds have recently modified their holdings of the company. California State Teachers Retirement System boosted its stake in shares of DaVita by 18,932.5% during the 2nd quarter. California State Teachers Retirement System now owns 8,610,866 shares of the company’s stock worth $1,915,745,000 after acquiring an additional 8,565,623 shares in the last quarter. HB Wealth Management LLC increased its stake in shares of DaVita by 27.0% in the 2nd quarter. HB Wealth Management LLC now owns 2,420 shares of the company’s stock valued at $538,000 after purchasing an additional 515 shares in the last quarter. Compass Financial Management LLC acquired a new position in DaVita in the 2nd quarter worth about $72,000. NEOS Investment Management LLC boosted its position in DaVita by 5.3% during the second quarter. NEOS Investment Management LLC now owns 5,021 shares of the company’s stock worth $1,117,000 after purchasing an additional 253 shares in the last quarter. Finally, Nykredit A S purchased a new position in DaVita during the second quarter worth approximately $1,062,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.